Literature DB >> 15643612

Mutation rates in the dystrophin gene: a hotspot of mutation at a CpG dinucleotide.

Carolyn H Buzin1, Jinong Feng, Jin Yan, William Scaringe, Qiang Liu, Johan den Dunnen, Jerry R Mendell, Steve S Sommer.   

Abstract

An analysis of mutations was performed in 141 Duchenne muscular dystrophy (DMD) patients previously found to be negative for large deletions by standard multiplex PCR assays. Comprehensive mutation scanning of all coding exons, adjacent intronic splice regions, and promoter sequences was performed by DOVAM-S, a robotically enhanced, high throughput method that detects essentially all point mutations. Samples negative for point mutations were further analyzed for duplications by multiplex amplifiable probe hybridization (MAPH). Presumptive causative mutations were detected in 90% of the patients (70% protein truncating point mutations, 13% duplications, and 7% deletions not detected by the standard multiplex screening method). A total of 40 of the mutations are putatively novel. Most duplications involve multiple exons with an average and median size of about 160 and 153 kb, respectively. This is the first analysis of the absolute and relative rates of point mutations in the dystrophin gene. Relative to microdeletions (0.68 x 10(-9) per bp per generation), transitions at CpG dinucleotides are enhanced 150-fold while complex indels, the least common mutation type, are less frequent than microdeletions by a factor of five. The frequency of microdeletions and microinsertions at mononucleotide repeats increases exponentially with length. When compared to the well-studied human factor IX gene (F9), the results are similar, with two exceptions: a hotspot of mutation in the dystrophin gene (c.8713C>T/p.R2905X) at a CpG dinucleotide and an altered size distribution of microdeletions. The hotspot reflects a difference in the underlying pattern of mutation, while the altered size distribution of microdeletions reflects certain abundant sequence motifs within the dystrophin coding sequence (relative to factor IX). (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15643612     DOI: 10.1002/humu.20132

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  21 in total

1.  Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy.

Authors:  Peter J Taylor; Sarah Maroulis; Glenda L Mullan; Robyn L Pedersen; Aurora Baumli; George Elakis; Sara Piras; Corrina Walsh; Benito Prósper-Gutiérrez; Fernando De La Puente-Alonso; Christopher G Bell; David R Mowat; Heather M Johnston; Michael F Buckley
Journal:  J Med Genet       Date:  2007-01-26       Impact factor: 6.318

2.  Screening human genes for small alterations performing an enzymatic cleavage mismatched analysis (ECMA) protocol.

Authors:  Nikolaos Vogiatzakis; Kyriaki Kekou; Christalena Sophocleous; Sophia Kitsiou; Ariadni Mavrou; Chrisa Bakoula; Emmanouel Kanavakis
Journal:  Mol Biotechnol       Date:  2007-08-03       Impact factor: 2.695

Review 3.  Challenges for gene therapy for muscular dystrophy.

Authors:  Jerry R Mendell; K Reed Clark
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

Review 4.  On the sequence-directed nature of human gene mutation: the role of genomic architecture and the local DNA sequence environment in mediating gene mutations underlying human inherited disease.

Authors:  David N Cooper; Albino Bacolla; Claude Férec; Karen M Vasquez; Hildegard Kehrer-Sawatzki; Jian-Min Chen
Journal:  Hum Mutat       Date:  2011-09-02       Impact factor: 4.878

5.  DMD mutation spectrum analysis in 613 Chinese patients with dystrophinopathy.

Authors:  Ruolan Guo; Guosheng Zhu; Huimin Zhu; Ruiyu Ma; Ying Peng; Desheng Liang; Lingqian Wu
Journal:  J Hum Genet       Date:  2015-05-14       Impact factor: 3.172

6.  Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy.

Authors:  Christopher Cunniff; Jennifer Andrews; F John Meaney; Katherine D Mathews; Dennis Matthews; Emma Ciafaloni; Timothy M Miller; John B Bodensteiner; Lisa A Miller; Katherine A James; Charlotte M Druschel; Paul A Romitti; Shree Pandya
Journal:  J Child Neurol       Date:  2008-12-12       Impact factor: 1.987

7.  Microarray-based mutation detection in the dystrophin gene.

Authors:  Madhuri R Hegde; Ephrem L H Chin; Jennifer G Mulle; David T Okou; Stephen T Warren; Michael E Zwick
Journal:  Hum Mutat       Date:  2008-09       Impact factor: 4.878

8.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort.

Authors:  Kevin M Flanigan; Diane M Dunn; Andrew von Niederhausern; Payam Soltanzadeh; Eduard Gappmaier; Michael T Howard; Jacinda B Sampson; Jerry R Mendell; Cheryl Wall; Wendy M King; Alan Pestronk; Julaine M Florence; Anne M Connolly; Katherine D Mathews; Carrie M Stephan; Karla S Laubenthal; Brenda L Wong; Paula J Morehart; Amy Meyer; Richard S Finkel; Carsten G Bonnemann; Livija Medne; John W Day; Joline C Dalton; Marcia K Margolis; Veronica J Hinton; Robert B Weiss
Journal:  Hum Mutat       Date:  2009-12       Impact factor: 4.878

9.  Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer.

Authors:  Zhenbin Chen; Jinong Feng; Carolyn H Buzin; Qiang Liu; Lawrence Weiss; Kemp Kernstine; George Somlo; Steve S Sommer
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

10.  Automated DNA mutation detection using universal conditions direct sequencing: application to ten muscular dystrophy genes.

Authors:  Richard R Bennett; Hal E Schneider; Elicia Estrella; Stephanie Burgess; Andrew S Cheng; Caitlin Barrett; Va Lip; Poh San Lai; Yiping Shen; Bai-Lin Wu; Basil T Darras; Alan H Beggs; Louis M Kunkel
Journal:  BMC Genet       Date:  2009-10-18       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.